-
131.发明申请公开(公告)号：US20180111989A1
公开(公告)日：2018-04-26
申请号：US15562602
申请日：2016-03-31
Inventor： Rifaat SAFADI
CPC classification number: C07K16/28 , A61K38/16 , A61K38/1709 , A61K38/177 , A61K2039/505 , A61P1/16 , C07K2317/34 , C07K2317/52 , C07K2317/76 , C07K2319/30
Abstract: Provided is a method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction. Also provided are compositions including the agent.
-
132.发明申请公开(公告)号：US20180099006A1
公开(公告)日：2018-04-12
申请号：US15837004
申请日：2017-12-11
Applicant: Hadasit Medical Research Services and Development Ltd. , B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
Inventor： Smadar COHEN , Yaron ILAN , Eyal SHTEYER , Ami BEN-YA'ACOV
IPC: A61K31/734 , A61K45/06 , A61K9/00 , A61K31/167
CPC classification number: A61K31/734 , A61K9/0053 , A61K31/167 , A61K45/06 , A61K2300/00
Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.
-
公开(公告)号：US20170281739A1
公开(公告)日：2017-10-05
申请号：US15507383
申请日：2015-09-21
Inventor： Yaron ILAN
IPC: A61K38/57
Abstract: Methods of treating liver diseases are provided. Accordingly there is provided a method of treating a liver disease selected from the group consisting of fatty liver disease and chronic liver rejection in a subject in need thereof, wherein said liver disease is not associated with genetic alpha-1 anti-trypsin (AAT) deficiency, the method comprising administering to the subject a therapeutically effective amount of AAT.
-
公开(公告)号：US09658216B2
公开(公告)日：2017-05-23
申请号：US14375195
申请日：2013-01-29
Inventor： Benjamin Eithan Reubinoff , Nurit Yachimovich-Cohen , Limor Matzrafi
CPC classification number: G01N33/56966 , C12N5/0621 , C12N2501/15 , C12N2501/16 , C12N2506/45 , C12N2509/00 , G01N21/6486 , G01N33/52 , G01N33/582 , G01N2021/4704 , G01N2333/46
Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
-
135.发明申请公开(公告)号：US20160317570A1
公开(公告)日：2016-11-03
申请号：US15206280
申请日：2016-07-10
Applicant: Hadasit Medical Research Services and Development Ltd. , Ben-Gurion University of the Negev Research and Development Authority
Inventor： Yaron ILAN , Gadi LALAZAR , Eyal SHTEYER , Ami BEN-YA'ACOV , Smadar COHEN , Tsiona ELKAYAM
IPC: A61K31/738
CPC classification number: A61K31/738 , A61K31/734 , A61L27/20 , A61L31/042 , A61P1/16 , C08L5/04
Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
Abstract translation: 本发明涉及在有需要的受试者中治疗肝脏疾病的方法。 更具体地，本发明的方法基于治疗有效量的至少一种生物相容性藻酸盐生物材料，其任何修饰以及它们的任何组合，优选全身施用。 本发明还提供了在患有肝脏障碍的受试者中维持血清白蛋白水平和/或降低血清AST和ALT的方法。 此外，本发明提供了使用本发明描述的藻酸盐生物材料减少患有肝脏疾病的受试者的损伤的肝组织中细胞凋亡和诱导细胞增殖的方法。
-
Patent Agency Ranking
136.发明授权Compositions and methods for amelioration and prevention of drug-induced toxicity 有权用于改善和预防药物毒性的组合物和方法公开(公告)号：US09474763B2
公开(公告)日：2016-10-25
申请号：US14551724
申请日：2014-11-24
Inventor： Josef Mograbi , Yaron Ilan
IPC: A61K31/357 , C07D309/36 , A61K31/661 , A61K45/06 , A61K31/10 , A61K31/167 , A61K31/198 , A61K31/685 , A61K31/7056 , A61K31/7076 , A61K31/197
CPC classification number: A61K31/661 , A61K31/10 , A61K31/167 , A61K31/197 , A61K31/198 , A61K31/357 , A61K31/685 , A61K31/7056 , A61K31/7076 , A61K45/06 , A61K2300/00
Abstract: Pharmaceutical compositions including combinations of protective agents selected from isosilybin B, methylsulfonylmethane (MSM), phosphatidylcholine, cysteine (Cys), seleno-cysteine (Se-Cys), ribose-cysteine (RibCys), N-acetylcysteine (NAC), N-acetylcysteine-amide (AD4), methionine (Met) and S-adenosylmethionine (SAM) for reducing and/or preventing drug-induced toxicity, such as acetaminophen-induced toxicity. The compositions may be formulated with or without acetaminophen, and accordingly may be used as safe formulations of acetaminophen with reduced risk of causing liver damage, or as an antidote for the treatment of acetaminophen overdose. Methods for treating acetaminophen intoxication.
Abstract translation: 药物组合物，包括选自异水滑石B，甲磺酰甲烷（MSM），磷脂酰胆碱，半胱氨酸（Cys），硒半胱氨酸（Se-Cys），核糖半胱氨酸（RibCys），N-乙酰半胱氨酸（NAC），N-乙酰半胱氨酸 酰胺（AD4），甲硫氨酸（Met）和S-腺苷甲硫氨酸（SAM），用于降低和/或预防药物诱导的毒性，如对乙酰氨基酚诱导的毒性。 组合物可以配制有或没有对乙酰氨基酚，因此可以用作对乙酰氨基酚的安全配方，降低引起肝损伤的风险，或作为治疗对乙酰氨基酚过量的解毒剂。 对乙酰氨基酚中毒治疗方法。
-
公开(公告)号：US20160227991A1
公开(公告)日：2016-08-11
申请号：US14891611
申请日：2014-05-16
Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. , HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventor： Itai Hayut , Elchanan Fried , Yaakov Nahmias , Tommy Weiss-Sadan , Ariel Shrem
CPC classification number: A61B1/06 , A61B1/00009 , A61B1/04 , A61B1/0661 , A61B1/267 , A61M16/0488
Abstract: A guided tracheal intubation system using an autonomous modulated light source, outputting modulated illumination at a constant level, and externally applied to the subject's larynx region. An optical imaging system receives a video stream from within the subject's throat, including modulated illumination from the subject's trachea. A display control system performs signal processing on the modulated content of the images, and outputs frames of those images in which the intensity level of illumination from the trachea can be controlled without any need to change the illumination output from the modulated light source. The light source has no connection with the rest of the system, and need contain no more than a battery, a power supply circuit and a light source. It can therefore be of low cost and can be made disposable, such as in the form of an adhesive patch applied to the subject's neck.
Abstract translation: 一种使用自主调制光源的引导气管插管系统，输出恒定水平的调制照明，并且外部施加于受试者的喉部区域。 光学成像系统从受试者的喉部内接收视频流，包括来自对象气管的调制照明。 显示控制系统对图像的调制内容执行信号处理，并且输出可以控制来自气管的照明强度水平的那些图像的帧，而不需要改变调制光源的照明输出。 光源与系统的其余部分无关，只需要包含电池，电源电路和光源。 因此，其可以是低成本的并且可以被制成一次性的，例如以施加到受试者的脖子的粘贴剂的形式。
-
公开(公告)号：US09301998B2
公开(公告)日：2016-04-05
申请号：US14081761
申请日：2013-11-15
Inventor： Tamar Peretz , Michal Lotem , Arthur Machlenkin , Shoshana Frankenburg , Inna Ben David , Anna Kuznetz , Yael Gelfand , Galit Eisenberg , Merav Darash Yahana
IPC: A61K39/00 , C12N5/09 , C12Q1/68 , G01N33/574
CPC classification number: A61K39/0011 , A61K2039/5152 , C12N5/0693 , C12Q1/6886 , G01N33/57492
Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
Abstract translation: 本发明涉及癌症免疫治疗，特别涉及同种异体肿瘤细胞疫苗。 根据一些实施方案，本发明提供可用作治疗性细胞疫苗组合物的新型细胞系。 本发明还提供了有利的筛选方法和手段，用于鉴定适合用部分人白细胞抗原（HLA）匹配的同种异体细胞疫苗治疗的患者。 进一步提供用于增殖性疾病的治疗组合物和方法。
-
139.发明申请DESFERRIOXAMINE-METAL COMPLEXES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS 有权用于治疗免疫相关疾病的DESFERRIOXAMINE-METAL复合物公开(公告)号：US20150148413A1
公开(公告)日：2015-05-28
申请号：US14606453
申请日：2015-01-27
Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD , HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventor： Mordechai Chevion , Vladimir Vinokur , Eduard Berenshtein , Ron Eliashar , Baruch Bulvik
IPC: A61K31/315 , A61K31/28
CPC classification number: A61K31/315 , A61K31/28 , A61K2300/00
Abstract: The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.
Abstract translation: 本发明涉及使用DFO-金属络合物的方法试剂盒和组合组合物，具体地，锌 - 去铁胺（Zn-DFO），镓 - 去铁三胺（Ga-DFO）复合物及其任何组合用于预防，治疗，改善或抑制免疫 相关疾病，具体地，皮肤相关的炎症性疾病如牛皮癣，炎症性呼吸病症如哮喘和自身免疫性疾病如糖尿病和任何免疫相关疾病。
-
公开(公告)号：US20150010922A1
公开(公告)日：2015-01-08
申请号：US14375195
申请日：2013-01-29
Inventor： Benjamin Eithan Reubinoff , Nurit Yachimovich-Cohen , Limor Matzrafi
IPC: G01N33/52
CPC classification number: G01N33/56966 , C12N5/0621 , C12N2501/15 , C12N2501/16 , C12N2506/45 , C12N2509/00 , G01N21/6486 , G01N33/52 , G01N33/582 , G01N2021/4704 , G01N2333/46
Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
Abstract translation: 公开了从混合细胞群中选择视网膜色素上皮（RPE）细胞的方法。 该方法包括：（a）分析混合细胞群体的细胞中至少一个以下参数：（i）自发荧光高于预定阈值的细胞; （ii）表达CD81高于预定阈值的细胞; 和（iii）将垂直于激光束的光散射到预定阈值以上的单元; 和（b）选择对至少一个参数是阳性的细胞，从而从混合的细胞群中分选RPE细胞。
-
-
-
-
-
-
-
-
-
Search Results
180
records
(took 0.033 seconds)
